Preclinical and Clinical Study on Type 3 Metabotropic Glutamate Receptors in Parkinson's Disease

Metabotropic glutamate (mGlu) receptors are candidate drug targets for therapeutic intervention in Parkinson's disease (PD). Here we focused on mGlu3, a receptor subtype involved in synaptic regulation and neuroinflammation. mGlu3 mice showed an enhanced nigro-striatal damage and microglial activation in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Expression of genes encoding anti-inflammatory proteins and neuroprotective factors was reduced in the striatum of MPTP-treated mGlu3 mice. We also examined polymorphic variants of GRM3 (the mGlu3 receptor encoding gene) in 723 PD patients and 826 healthy controls. Two GRM3 haplotypes were associated with PD, and gene variants correlated with motor and non-motor signs. Interestingly, PD patients carrying each of the two haplotypes showed an impaired cortical plasticity in the paired associated stimulation paradigm of magnetic transcranial stimulation. These findings suggest that mGlu3 receptors are neuroprotective in mouse models of parkinsonism and shape mechanisms of cortical plasticity in PD.

References

Masilamoni G, Bogenpohl J, Alagille D, Delevich K, Tamagnan G, Votaw J . Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain. 2011; 134(Pt 7):2057-73. PMC: 3122374. DOI: 10.1093/brain/awr137. View

Shulman L, Gruber-Baldini A, Anderson K, Vaughan C, Reich S, Fishman P . The evolution of disability in Parkinson disease. Mov Disord. 2008; 23(6):790-6. DOI: 10.1002/mds.21879. View

Luchtman D, Shao D, Song C . Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol Behav. 2009; 98(1-2):130-8. DOI: 10.1016/j.physbeh.2009.04.021. View

Yan A, Liu Z, Song L, Wang X, Zhang Y, Wu N . Idebenone Alleviates Neuroinflammation and Modulates Microglial Polarization in LPS-Stimulated BV2 Cells and MPTP-Induced Parkinson's Disease Mice. Front Cell Neurosci. 2019; 12:529. PMC: 6333870. DOI: 10.3389/fncel.2018.00529. View

Rascol O, Medori R, Baayen C, Such P, Meulien D . A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease. Mov Disord. 2022; 37(5):1088-1093. PMC: 9303267. DOI: 10.1002/mds.28970. View

Sole X, Guino E, Valls J, Iniesta R, Moreno V . SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006; 22(15):1928-9. DOI: 10.1093/bioinformatics/btl268. View

Langston J, FORNO L, Rebert C, Irwin I . Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res. 1984; 292(2):390-4. DOI: 10.1016/0006-8993(84)90777-7. View

Gundersen H, Jensen E . The efficiency of systematic sampling in stereology and its prediction. J Microsc. 1987; 147(Pt 3):229-63. DOI: 10.1111/j.1365-2818.1987.tb02837.x. View

Bologna M, Suppa A, Conte A, Latorre A, Rothwell J, Berardelli A . Are studies of motor cortex plasticity relevant in human patients with Parkinson's disease?. Clin Neurophysiol. 2015; 127(1):50-59. DOI: 10.1016/j.clinph.2015.02.009. View

10.

Guo L, Xiong H, Kim J, Wu Y, Lalchandani R, Cui Y . Dynamic rewiring of neural circuits in the motor cortex in mouse models of Parkinson's disease. Nat Neurosci. 2015; 18(9):1299-1309. PMC: 4551606. DOI: 10.1038/nn.4082. View

11.

Caraci F, Molinaro G, Battaglia G, Giuffrida M, Riozzi B, Traficante A . Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of.... Mol Pharmacol. 2010; 79(3):618-26. DOI: 10.1124/mol.110.067488. View

12.

Battaglia G, Busceti C, Molinaro G, Biagioni F, Storto M, Fornai F . Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci. 2004; 24(4):828-35. PMC: 6729818. DOI: 10.1523/JNEUROSCI.3831-03.2004. View

13.

Schober A, Hertel R, Arumae U, Farkas L, Jaszai J, Krieglstein K . Glial cell line-derived neurotrophic factor rescues target-deprived sympathetic spinal cord neurons but requires transforming growth factor-beta as cofactor in vivo. J Neurosci. 1999; 19(6):2008-15. PMC: 6782553. View

14.

Munoz-Manchado A, Villadiego J, Romo-Madero S, Suarez-Luna N, Bermejo-Navas A, Rodriguez-Gomez J . Chronic and progressive Parkinson's disease MPTP model in adult and aged mice. J Neurochem. 2015; 136(2):373-87. DOI: 10.1111/jnc.13409. View

15.

Nicoletti F, Bockaert J, Collingridge G, Conn P, Ferraguti F, Schoepp D . Metabotropic glutamate receptors: from the workbench to the bedside. Neuropharmacology. 2010; 60(7-8):1017-41. PMC: 3787883. DOI: 10.1016/j.neuropharm.2010.10.022. View

16.

Sartorius L, Weinberger D, Hyde T, Harrison P, Kleinman J, Lipska B . Expression of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals carrying a schizophrenia risk SNP. Neuropsychopharmacology. 2008; 33(11):2626-34. DOI: 10.1038/sj.npp.1301669. View

17.

Maj C, Minelli A, Giacopuzzi E, Sacchetti E, Gennarelli M . The Role of Metabotropic Glutamate Receptor Genes in Schizophrenia. Curr Neuropharmacol. 2016; 14(5):540-50. PMC: 4983747. DOI: 10.2174/1570159x13666150514232745. View

18.

Battaglia G, Molinaro G, Riozzi B, Storto M, Busceti C, Spinsanti P . Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons. PLoS One. 2009; 4(8):e6591. PMC: 2719807. DOI: 10.1371/journal.pone.0006591. View

19.

Bologna M, Guerra A, Paparella G, Giordo L, Fegatelli D, Vestri A . Neurophysiological correlates of bradykinesia in Parkinson's disease. Brain. 2018; 141(8):2432-2444. DOI: 10.1093/brain/awy155. View

20.

Belvisi D, Fabbrini A, De Bartolo M, Costanzo M, Manzo N, Fabbrini G . The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes. Mov Disord. 2020; 36(2):370-379. DOI: 10.1002/mds.28321. View